Kestra Medical Technologies reports developments as a commercial-stage wearable medical device and digital healthcare company focused on cardiovascular disease. Its updates center on the Cardiac Recovery System platform and the ASSURE WCD, a wearable cardioverter defibrillator used for patients at elevated risk of sudden cardiac arrest.
Recurring news includes fiscal results and revenue guidance, clinical data from the ASSURE WCD post-approval study, product and algorithm updates, healthcare conference presentations, and collaborations aimed at expanding diagnostic insight during cardiac recovery.
Kestra Medical Technologies (Nasdaq: KMTS) announced a proposed underwritten public offering of 5,500,000 common shares with a 30-day underwriter option to purchase up to an additional 825,000 shares, subject to market conditions and SEC effectiveness of the registration statement (as of Dec 1, 2025).
The company intends to use proceeds to support sales and marketing, ongoing commercialization, further fund research, development and clinical studies, and for working capital and general corporate purposes. All offered shares are being sold by Kestra. Bookrunners include BofA Securities, Piper Sandler, J.P. Morgan, Goldman Sachs and Wells Fargo Securities. The offering may not occur and terms may change.
Kestra Medical Technologies (Nasdaq: KMTS) reported preliminary Q2 fiscal 2026 results for the quarter ended October 31, 2025, showing continued commercial momentum in the wearable defibrillator market. Revenue is expected to be $22.2–$22.6M, up ~52% at the midpoint versus prior year. Gross profit is expected to be $11.0–$11.4M and gross margin is expected near 50.0% versus 39.6% prior year. Loss from operations is expected to be $31.6–$32.0M. Cash and cash equivalents are expected to be approximately $175M. Results are preliminary and subject to adjustment; final results will appear in the Form 10-Q filed in December 2025.
Kestra Medical Technologies (Nasdaq: KMTS) announced primary results from ACE-PAS, the largest prospective real-world study of wearable defibrillators, presented at AHA Scientific Sessions 2025.
The study enrolled 21,612 patients and showed 100% successful conversion of VT/VF events versus the prespecified goal; an inappropriate-shock rate of 0.0065 per patient-month; 94% of patients had no false positive shock alarms; 2.6% experienced at least one life-threatening VT/VF; ASSURE detected 4.2% high-rate atrial fibrillation (35% newly diagnosed) and 0.3% severe bradycardia/asystole. Median wear time exceeded 23 hours/day, with one-third using the device beyond 90 days.
Kestra Medical Technologies (Nasdaq: KMTS) will present late-breaking results from the ACE-PAS trial at the American Heart Association Scientific Sessions 2025 on Nov 10, 2025 at 8:44 a.m. CT (Session 211–213).
ACE-PAS is a post-approval, real-world evaluation of the next-generation ASSURE wearable cardioverter defibrillator, enrolling more than 20,000 patients across the U.S., and is described as the largest prospective WCD study to date. Primary endpoints include overall shock conversion success and inappropriate shock rate; additional measures: first shock conversion success, median daily wear time, and false alarm rate.
Kestra will also host live demonstrations and an immersive in-booth experience at booth #4617 during AHA Nov 7–10, highlighting its Cardiac Recovery System and connected care tools.
Kestra Medical Technologies (Nasdaq: KMTS) will present at the Stifel 2025 Healthcare Conference on Tuesday, November 11, 2025 at 3:20 p.m. ET.
Investors and interested parties can watch a live webcast and later view a replay on the Kestra Medical Technologies investor relations website.
Kestra Medical Technologies (Nasdaq: KMTS) appointed Timothy Moran as Chief Business Officer, effective November 3, 2025. In the role Moran will lead business strategy, corporate business development, payor engagement and contracting, reimbursement strategy, and revenue cycle management.
Moran brings over 25 years in medtech, most recently serving as president and CEO at Avertix Medical where he led a launch of a first‑to‑market implantable cardiac device, and previously as CEO of Motus GI Holdings. Management expects Moran to support the company’s commercial ramp, advance payor and provider partnerships, and accelerate adoption of the Cardiac Recovery System and ASSURE® WCD.
Kestra Medical Technologies (Nasdaq: KMTS) announced its participation in the 2025 Heart Failure Society of America (HFSA) Annual Scientific Meeting in Minneapolis. The company will showcase its Cardiac Recovery System® (CRS) platform, featuring the ASSURE® Wearable Cardioverter Defibrillator at booth #920.
The CRS platform aims to enhance sudden cardiac death protection by combining protective measures with actionable insights during critical heart failure recovery phases. Visitors can experience hands-on demonstrations of the platform, which focuses on strengthening patient-provider connections and supporting vulnerable patients' recovery.
Kestra Medical Technologies (Nasdaq: KMTS), a wearable medical device and digital healthcare company, has appointed Dr. Elizabeth Kwo as an independent director to its board of directors. Dr. Kwo currently serves as Chief Commercial Officer of Everly Health and brings extensive experience in digital health platforms and data-driven care models.
Dr. Kwo's background includes roles as Deputy Chief Clinical Officer at Anthem, VP and GM of Provider Networks at American Well, and Entrepreneur in Residence at Harvard Medical School. She is board certified in preventive care and occupational medicine, holding degrees from Harvard Medical School (MD), Harvard School of Public Health (MPH), Harvard Business School (MBA), and Stanford University (BA).
Kestra Medical Technologies (Nasdaq: KMTS) reported strong Q1 FY26 financial results, with revenue reaching $19.4 million, a 52% increase year-over-year. The wearable medical device company saw significant growth with 4,205 prescriptions written for its ASSURE® system, up 51% from the previous year. Gross margin expanded to 45.7% from 32.9% year-over-year.
The company raised its FY26 revenue guidance to $88 million, representing 47% growth compared to FY25, up from previous guidance of $85 million. Despite strong top-line growth, Kestra reported a GAAP net loss of $25.8 million and held cash and equivalents of $201.2 million as of July 31, 2025.
Kestra Medical Technologies (Nasdaq: KMTS), a wearable medical device and digital healthcare company, has scheduled its first quarter fiscal 2026 earnings release for Thursday, September 11. The company will host a conference call at 4:30 p.m. Eastern Time to discuss the results.
Interested participants can access the live and archived webcast through the "Events" section of Kestra's investor relations website and are advised to register at least 10 minutes before the call begins.